Influenza A/New Caledonia/20/99 (H1N1) virus was studied for development of resistance to cyanovirin-N (CVN). CVN neutralizes virus infectivity by binding to specific high-mannose oligosaccharides on the viral haemagglutinin 1 (HA1) subunit. During virus adaptation to mice in the absence of CVN treatment the virus became resistant to CVN (CVN-MR virus), as did virus passaged in cell culture in the presence of CVN (CVN-R virus). The CVN-R virus possessed a single amino acid change at position 94a (Asn94aAsp) of HA1 that eliminated this glycosylation site. The CVN-MR virus at mouse passage 7 was a mixture of clones, consisting of a single mutation (Asp225Gly) and double mutations (Asn63Ser+Asp225Gly or Asn94a+Asp225Gly), eliminating glycosylation sites. CVN did not bind well to the CVN-R and CVN-MR viruses. Propagating these viruses in cells treated with 1 mM deoxymannojirimycin (dMJ, mannosidase inhibitor) increased sensitivity to CVN, suggesting that glycans attached at other sites on HA1 that typically are not high-mannosidic became so due to dMJ treatment. Further evaluation showed that the Asp225Gly mutant virus was sensitive to the inhibitor and did not kill mice or induce weight loss. The CVN-R virus was also avirulent to mice. The double-mutant CVN-MR viruses were resistant to CVN and caused deaths and severe weight loss in mice. CVN-R virus subjected to mouse adaptation acquired the 225 mutation and a lethal phenotype. Thus, the 225 mutation in the HA receptor-binding site in combination with a loss of glycan at Asn (63 or 94a) are important for mouse adaptation in this virus. The mutations reported here causing resistance to CVN are consistent with its known mode of action.
One of the important changes occurring during the adaptation of influenza viruses to mice is the loss of glycosylation sites (Hartley et al., 1997; Govorkova et al., 2000) . A potential glycosylation site motif is a sequence of three amino acids. The first is always asparagine, the second one could be any amino acid except proline and the third one must be either serine or threonine. These sites have been shown to be important for virus neutralization by host mannose-binding lectins, termed collectins (Anders et al., 1990; Reading et al., 1997; Hartshorn et al., 2000) . Thus, the viruses undergo mutation in order to avoid neutralization by these host defense substances. We have been studying the antiviral protein cyanovirin-N (CVN) that has a mode of action against influenza viruses similar to host collectins. CVN is a 101 amino acid protein isolated from the cyanobacterium Nostoc ellipsosporum. It exhibits antiviral activity by binding to highmannose (oligomannose-8 and oligomannose-9; Man-8 and Man-9) residues on the viral haemagglutinin 1 (HA1) molecule, resulting in virus neutralization . The protein neutralizes other unrelated viruses such as HIV by the same mechanism (Boyd et al., 1997; O'Keefe et al., 2000; Bolmstedt et al., 2001; Shenoy et al., 2001; Barrientos et al., 2003) .
CVN has been studied for antiviral activity against a number of influenza virus strains, some of which are resistant to CVN (O'Keefe et al., 2003) . It became apparent that there was a correlation between viral strain resistance to CVN and the ability of the virus to kill mice. This has hampered our ability to test the antiviral activity of the protein in vivo, but provided an opportunity to explore the nature of resistance of mouse-adapted influenza viruses to the inhibitor. In this report a number of different influenza virus strains were evaluated for their sensitivity to neutralization by CVN. A/New Caledonia/20/99 (H1N1), a virus that was until recently in the trivalent influenza vaccine, was selected for further examination, and was subjected to mouse adaptation and to replication in cell culture in the presence of increasing concentrations of CVN. Both methods of propagating the virus produced CVN-resistant viruses that were later analysed for mutations. The data derived from the two new virus pools helps in understanding the mode of virus resistance to CVN.
Materials and methods

Antiviral protein and cells
Purified recombinant CVN was produced in Escherichia coli as reported previously (Mori et al., 1998) . Madin-Darby canine kidney (MDCK) cells (obtained from the American Type Culture Collection, Manassas, VA, USA) were grown in antibiotic-free minimum essential medium with non-essential amino acids (MEM; Gibco, Long Island, NY, USA) containing 5% fetal bovine serum (HyClone Laboratories, Logan, UT, USA) and 0.1% NaHCO 3 . Virus propagation medium was MEM without serum, 0.18% NaHCO 3 , 10 units/ml trypsin, 1 mg ethylenediaminetetraacetate/ml and 50 mg gentamicin/ml. MDCK cells were used for all cell culture studies with virus and CVN.
Viruses
The following viruses were provided by the Influenza Branch of the Centers for Disease Control and Prevention (Atlanta, GA, USA): A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), B/Hong Kong/330/02 and B/Sichuan/379/99. The sources for the other viruses used in these studies (Table 1) were indicated previously (Smee et al., 2001) . All viruses except A/NWS/33 (H1N1) and A/PR/8/34 (H1N1) were passaged no more than three times in MDCK cells to prepare pools for use in the cell culture experiments. The A/NWS/33 and A/PR/8/34 viruses are laboratory strains that have been passaged a considerable number of times in cell culture and in mice before we acquired them. Some of the viruses were received from the supplier as egg-passaged virus pools and were then further replicated in MDCK cells. This may have altered the viral HA1 structure (loss of a glycosylation site), as will be shown by the A/New Caledonia/20/99 (H1N1) virus.
The influenza A/New Caledonia/20/99 (H1N1) virus was passaged in our laboratory seven times in mice (10-12 g BALB/c, from Charles River labs, Wilmington, MA, USA) to increase its virulence. Lungs were harvested at each dilution and 1:10 homogenates were made and frozen at -80˚C. Mice were infected intranasally with 50 μl of virus diluted twofold for the next infection (passage). Ketamine (100 mg/kg given intraperitoneally) anesthesia was used to facilitate infection of the lungs. Some of the mice died from the infection at passage six and all the animals died by passage 7. This final passage resulted in a virus resistant to CVN (CVN-MR virus). The virus was also propagated in the presence of increasing concentrations of CVN in cell culture starting at 0.02 mg/ml, until it was able to replicate in 10 mg/ml (CVN-R virus). For some studies, the A/New Caledonia/20/99 (H1N1) virus isolates (wild-type, CVN-MR and CVN-R viruses) were replicated in the presence of 1 mM castanospermine (Cs), deoxymannojirimycin (dMJ) or deoxynojirimycin (dNJ; all from Sigma, St. Louis, MO, USA). Other investigators have shown that HIV-1 replicated in the presence of dMJ exhibited enhanced lectin-binding properties (Hart et al., 2003) , thus treating infected cells with dMJ was predicted to enhance CVN binding to influenza virus particles.
As influenza viruses can rapidly mutate in cell culture or during animal passage, the viruses used in these studies may represent mixtures of quasispecies. Antiviral studies were performed with these viruses, except where indicated that clones of individual viruses were used.
Antiviral assays
We have previously determined that CVN prevented virus from entering cells . Thus, in order to evaluate the sensitivities of various strains of virus to CVN, a virus neutralization assay was used. Viruses were diluted to approximate titres of 10 5 -10 6 cell culture infectious doses per 0.1 ml. Some viruses did not replicate to those titre levels and were used undiluted. Each virus preparation was then incubated with an equal part of CVN (final concentration of 10 μg/ml) for 30 min at room temperature followed by endpoint dilution (10-fold increments) in 96-well plates of MDCK cells, using four microwells per virus dilution. This diluted both virus and CVN in the medium. Untreated virus was combined with an equal part of cell culture medium and similarly titrated. Viral cytopathic effect (CPE) was recorded from wells 6 days later, and virus titres were calculated by the method of Reed and Muench (1938) , and are included for comparative purposes (Table 1) .
Confirmatory virus yield reduction assays (mean data from three independent experiments) were performed in 96-well plates with A/New Caledonia/20/99 (H1N1) wild-type, CVN-R and CVN-MR viruses using a previously described method (Smee et al., 2001) . Briefly, CVN was added to microplates at varying half-log 10 concentrations and virus at approximately 50-100 50% cell culture infectious doses per well was added 5-10 min later. At 72 h, when CPE due to virus was maximal in untreated control wells, the plates were frozen at -80 o C. Virus from wells was subsequently titrated by endpoint dilution in 96-well plates of MDCK cells as described above.
Viral CPE inhibition assays were conducted in 96-well plates of MDCK cells by evaluating CVN at half-log 10 dilutions applied to cells 5-10 min prior to infecting with viral clones. At 3 days, when virus control cells were completely destroyed, the extent of viral CPE was determined visually and by a neutral red dye uptake assay (Smee et al., 2001) . Fifty percent inhibitory concentrations of CVN versus each virus were calculated by linear regression of compound concentration versus percent inhibition on semi-log paper.
Genetic characterization of influenza A/New Caledonia/20/99 (H1N1) mutants
The CVN-R and CVN-MR viruses at various passages and the wild-type virus (passaged twice in MDCK cells; this was the original starting virus used to generate the resistant viruses) were analysed genetically to determine the mutations accounting for CVN resistance. The procedure used for the genetic analysis was that of Mishin et al. (2005) . The sequences of the viral HA1 and HA2 subunits and neuraminidase (NA) were compared against the sequences published in GenBank. In particular, we were interested in mutations that eliminated putative glycosylation sites on the surface of the virus associated with mouse adaptation and resistance to Data represent means ±SD for three independent determinations. *Untreated viruses were combined with an equal part of culture medium. † Virus and cyanovirin (CVN; 10 μg/ml final concentration) were combined for 30 min prior to titration. ‡ Previously reported in O' Keefe et al. (2003) . § This is the CVN-MR virus (virus resistant to CVN during mouse adaption) and above it is the wild-type virus. ¶ Mouse-adapted (seven in vivo passages) for lethality. CCID 50 , 50% cell culture infectious dose.
Table 1. Virus neutralizing activity of CVN against various strains of influenza A and influenza B viruses
CVN. The HA amino acid numbering is given according to Winter et al. (1981) .
CVN-binding assay
CVN was previously shown to bind to influenza, HIV-1 and Ebola virus particles (Boyd et al., 1997; Shenoy et al., 2001; Barrientos et al., 2003; O'Keefe et al., 2003) . Binding studies conducted here used 100 μl of influenza virus lysates containing the same number of virus particles of either the starting wild-type strain of influenza A/New Caledonia/20/99 (H1N1) or various subsequently derived strains (CVN-R, CVN-MR and progeny viruses replicated in cells treated with 1 mM dMJ). Viruses were bound to the wells of a 96-well plate by incubation for 2 h at room temperature. Thereafter, the plates were washed three times with phosphate-buffered solution augmented with 0.05% Tween 20 (TPBS), then blocked by the addition of 200 μl/well of a solution of 1% bovine serum albumin (from Sigma) in PBS, followed by overnight incubation at 4˚C and a further wash with TPBS. Various dilutions of CVN (0.05-500 ng/well) were then added to the wells of the plates and incubated for 1 h at room temperature with gentle rocking. After again washing with TPBS as above, the plates were then incubated with a 1:1,000 dilution of rabbit-anti-CVN polyclonal antibodies for 1 h. Again after washing with TPBS as above, the plates were incubated for 1 h with a 1:1,000 dilution of goat-anti-rabbit polyclonal antibodies that had been tagged with europium. After washing three more times with TPBS, 100 ml of enhancement solution (Perkin Elmer, Wellesley, MA, USA) was added to each well on the plates and the plates were monitored for time-resolved fluorescence from the free europium.
Results
CVN neutralization of virus infectivity
What led to the present studies were assay results showing that certain strains of influenza viruses were naturally resistant to CVN (O'Keefe et al., 2003) . This prompted an investigation of a larger number of influenza virus strains for neutralization by the protein ( Figure 1A shows the development of resistance of the CVN-MR virus with successive passages in mice. Even after a single passage there was a shift in sensitivity to CVN. The virus became partially lethal to mice at passage 6 (33% mortality) and by passage 7 the virus pool was fully virulent (100% mortality). Thus, the decrease in sensitivity to CVN preceded the ability of the virus to kill mice. The CVN-R virus prepared in cell culture was assayed at each successive passage ( Figure 1B) . Resistance to the inhibitor was seen with two passages of the virus in the presence of CVN. To confirm resistance of the viruses to CVN by another method, virus yield reduction assays were performed in MDCK cells (Figure 2 ). CVN was inhibitory to wild-type virus at concentrations of >0.1 μg/ml, whereas much greater virus production occurred with the CVN-R and CVN-MR viruses at these inhibitory concentrations.
Genetic and phenotypic analysis of the CVNresistant influenza A/New Caledonia/20/99 (H1N1) HA1
The original wild-type, CVN-R and CVN-MR viral HA1 genes were analysed for mutations that may be associated with CVN resistance (Table 2 ). An amino acid change occurred at positions 129 (Asn129Thr), a putative glycosylation site, as a result of MDCK cell culturing of the original virus. As this mutation was in the wild-type (2MDCK) virus as well as in the CVN-MR and CVN-R viruses, the mutation was deemed to play no role in resistance to CVN. An important mutation occurred in the CVN-R virus, causing a loss of the glycosylation site at position 94a (Asn94aAsp). This single mutation would render CVN unable to bind to the virus at that position of the HA1 subunit. The CVN-MR virus contained a mixture of several virus clones isolated from a pool of lung homogenates (bottom of Table 2 ). Clones 8 and 11 were wild-type virus; clones 4, 5, 7, 9 and 12 contained an Asp225Gly mutation; clone 1 contained a double mutation Asn63Ser and Asp225Gly; and Clones 2, 3, 6 and 10 contained the double mutation Asn94aAsp and Asp225Gly.
Clones 1, 2, 11 and 12 were tested for sensitivity to CVN in cell culture and for their ability to kill 10-12 g BALB/c mice. Clones 11 and 12 were sensitive to CVN in a CPE inhibition assay (being inhibited by 50% at concentrations of 0.02-0.06 μg/ml). These clones were completely avirulent to mice, causing no death and inducing no weight loss. Clones 1 and 2 were resistant to CVN in cell culture (50% inhibitory concentrations of 0.5-1.1 μg/ml). These clones caused death (20% mortality with clone 1 and 100% mortality with clone 2) and induced severe weight loss in mice during the infections.
Adaptation of the CVN-R virus to mice and its genotypic analysis
The CVN-R virus that was resistant to the inhibitor as a result of cell culture passage (Asn94aAsp mutation) was passaged seven times in mice to develop virulence. The virus was not initially lethal to the animals, indicating that this mutation alone was not sufficient for lethality. The resulting virus that was 100% lethal to the animals was sequenced for mutations in the HA1 protein. The resulting virus had two mutations: Asn94aAsp (present before mouse passage) and Asp225Gly. Thus, this virus was the same in HA1 sequence as clones 2, 3, 6 and 10 above.
Effects of glycosylation inhibitors on the ability of progeny virus particles to be neutralized by CVN
As CVN binds only to Man-8 and Man-9 residues, we hypothesized that CVN-R virus and CVN-MR virus Cyanovirin (CVN) was exposed to cells just prior to virus infection and then the virus was cultured for three days. Progeny virus was titrated later on fresh monolayers of Madin-Darby canine kidney cells. Data represent means ±SD for three independent determinations. CCID 50 , 50% cell culture infectious dose; CVN-MR virus, virus resistant to CVN during mouse adaption; CVN-R virus, virus resistant to CVN during cell culture; WT, wild type. clones lacking glycosylation sites either at positions 63 or 94a poorly bind CVN. However, these are not the only glycosylation sites on the HA1 molecule where the molecule could bind. Other glycosylation sites are located at positions 21/22, 33, 129 (lost during MDCK cell adaptation), 163 and 289 of the HA1 subunit. These sites may not necessarily be glycosylated and/or may contain glycans of a different chemical composition due to glycan trimming that occurs in the cell. Assuming this is the case, glucosidase and mannosidase inhibitor can be used as tools to alter glycosylation and study their effects on progeny viruses. To explore this possibility, wild-type (2MDCK), CVN-R and CVN-MR viruses were replicated in MDCK cells treated with 1 mM of glucosidase inhibitors Cs and dNJ, or the mannosidase inhibitor dMJ, following which the ability of CVN to neutralize progeny virus infectivity was assessed ( Figure 3A) . Wildtype virus produced from Cs-and dNJ-treated cells was resistant to CVN, which is explained by these inhibitors blocking the formation of Man-8 or Man-9 (Figure 4 ) on the surface of the virus, thus preventing CVN binding. Wild-type, CVN-MR and CVN-R progeny viruses produced from dMJ-treated cells were more sensitive to inhibition by CVN than the parental viruses. Since dMJ blocks conversion of Man-8 (that does bind CVN) to Man-7 (that does not bind CVN), the progeny viruses must contain a higher amount of Man-8 and/or Man-9 residues than the parental viruses in order to be neutralized to a greater extent. Viruses lacking glycosylation sites either at position 63 or 94a must possess increased amounts of Man-8 and/or Man-9 at the other remaining glycosylation sites on the HA1 molecule.
Binding of CVN to virus particles
With a loss of glycosylation sites on HA1, less CVN should bind to the virus particle. The extent of CVN binding to the wild-type, CVN-R and CVN-MR viruses was determined by using a europium-tagged antibody to bind CVN ( Figure 5) . The CVN-MR and CVN-R viruses had less CVN bound to them than was bound to the wild-type virus, thus supporting this hypothesis. The data also show that some CVN was bound to these mutant viruses, which would have to be at the other glycosylation sites (these sites may not influence the ability of the virus to infect cells).
Discussion
There has been a trend over time for influenza A viruses in humans to increase in the number of HA glycosylation sites (Abe et al., 2004) . This has been explained as a means for viruses to avoid neutralization by host antibodies. Winter et al. (1981) . † The number of potential glycosylation sites in HA1 out of seven possible glycosylation sites in HA1 of the wild-type A/New Caledonia/20/99 (the glycosylation site at 129 was lost during MDCK cell adaptation). ‡ Passage number in cells in the presence of cyanovirin (CVN). § Passage number in mice. ¶ Mixtures of viruses were developing in the pool, as evidenced by their presence in passage 7. Some of the isolated clones in passage 7 pool were CVN-resistant, so there must have been an increasing number of resistant viruses with each passage. MDCK, Madin-Darby canine kidney cells. Table 2 . Amino acid substitutions in the HA1 protein arising during mouse adaptation in the absence of CVN and during cell culture selection in the presence of CVN However, such viruses can be more readily neutralized by host defense collectins (Anders et al., 1990; Reading et al., 1997; Hartshorn et al., 2000) . Thus, a tradeoff exists between neutralization by antibodies versus neutralization by collectins. As CVN acts in a manner similar to collectins, the compound may be useful in the prophylaxis or early treatment of influenza virus infection. Based upon the data in Table 1 , influenza A viruses would more likely be inhibited than influenza B viruses. To date, no reports have been published regarding the efficacy of CVN in animal models. Presumably the compound would need to be topically applied by intranasal drops or by aerosolization. Work in mice has been hampered by the fact that mouse-adapted viruses are resistant to CVN, as The viruses were grown in the presence of glycosylation inhibitors (1 mM) then the progeny virus was tested for sensitivity to neutralization by CVN (10 μg/ml). Data represent means ±SD for three independent determinations. Cs, castanospermine; dMJ, deoxymannojirimycin; dNJ, deoxynojirimycin.
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shown here. Ferrets may pose as an alternative non-lethal model for anti-influenza virus testing of CVN because they are capable of being infected with non-adapted human influenza virus strains (Sidwell & Smee, 2004) .
In the present studies, CVN was used as a probe for changes in HA glycoprotein structure resulting from point mutations in the viral gene. This was possible because CVN binds only to Man-8 and Man-9 structures (O'Keefe et al., 2003) , resulting in neutralization of virus infectivity. CVN-resistant viruses that were prepared in cell culture and in mice lacked glycosylation sites at positions 63 and 94a on the HA1 molecule. This resulted in decreased binding of CVN to CVN-R and CVN-MR virus particles compared with wild-type virus ( Figure 5 ).
Many investigators have indicated that a mutation at position 94 (or 94a, depending upon the nomenclature) of the viral HA1 is important for adaptation of influenza viruses to mice (Hartley et al., 1997; Govorkova et al., 2000) . Host cell collectins bind to this site to neutralize virus infectivity. For this reason, it was not surprising to find that the some of the influenza A/New Caledonia/20/99 (H1N1) viruses isolated during mouse passage (CVN-MR virus) had mutations at position 94a of HA1. Other viral clones that were isolated were mutated at position 63, resulting in loss of this glycosylation site. Both the 63 and 94a virus clones were resistant to CVN. Another mutation (Asp225Gly) arose earlier in the course of mouse adaptation, but this mutation did not confer resistance to CVN. This same mutation arose when the CVN-R cell culture-derived virus containing the 94a mutation was passaged in mice to obtain a virulent virus. The importance of the 225 mutation on the HA1 molecule for receptor binding was recently demonstrated in studies with the newly recreated 1918 influenza A (H1N1) virus (Tumpey et al., 2007) . This site on the virus, when mutated, rendered the virus less transmissible in ferrets. From the work reported here, the mutation in mice appears to be important in the adaptive process of the A/New Caledonia/20/99 (H1N1) virus to mice because it was frequently isolated. Resistance that developed by cell culture passage of the virus in the presence of CVN (CVN-R virus) showed a single point mutation (Asn94aAsp) at position 94a. Its loss rendered the virus resistant to CVN, as demonstrated by virus neutralization and virus yield reduction assays ( Figures 1B and 2) . This virus was unable to kill mice initially, but did so DF Smee et al. 324 ©2008 following mouse adaptation and the acquisition of the Asp225Gly mutation. What was confusing was the drop in virus sensitivity to CVN in the early passages of the CVN-MR virus ( Figure 1A) . At first we thought that the Asp225Gly mutation, which was the first mutation detected, was responsible for causing resistance to CVN. Later, a clone of the Asp225Gly-containing virus was shown to be CVN-sensitive. After considering the data in its entirety, it is our hypothesis that this difference in sensitivity between the MDCK cell-passaged wild-type virus and the early-passaged virus in mice must not be due to genetics. Instead, it may relate to how MDCK and mouse lung cells glycosylate the virus particles, rendering one source of virus more sensitive to CVN than the other. This explanation seems plausible, based on the fact that no other mutations than the CVN-sensitive Asp225Gly mutation were detected early in the mouse passage of the virus. As additional support of this hypothesis, coronaviruses have been shown to vary in their sensitivity to inhibition by mannose-binding plant lectins depending upon the cell type used to grow the virus stocks (van der Meer et al., 2007) .
Treatment of cells during infection with glucosidase and mannosidase inhibitors changed the glycoprotein structure of the progeny virus particles, as determined by the ability of CVN to neutralize these viruses. Specifically, treatment of cells with the glucosidase inhibitors Cs and dNJ rendered progeny wild-type virus resistant to CVN. These viruses must be devoid of Man-8 and Man-9 residues on the viral HA1 glycoproteins. The mannosidase inhibitor dMJ rendered the progeny wild-type virus more sensitive to CVN, indicating that Man-8 and Man-9 residues were more abundant on the surface of the virus particles. The CVN-R and CVN-MR viruses were already resistant to CVN, so glucosidase treatment did not change this property. However, treatment of cells with dMJ caused progeny CVN-R and CVN-MR viruses to become sensitive to CVN. Such treatment would cause viral glycosylation sites (which are at positions 21/22, 33, 63 [lost in certain clones of the CVN-MR virus], 94a [lost in the CVN-R virus, and in certain clones of the CVN-MR virus], 129 [lost during MDCK cell adaptation], 163 and 289) to be maintained with Man-8 or Man-9 structures (thus promoting CVN binding), rather than be modified enzymatically. Recently, van der Meer and colleagues (2007) demonstrated that mannosidase treatment of coronavirus-infected cells rendered them more sensitive to inhibition by mannose-binding plant lectins. This is analogous to what was seen with influenza H1N1 virus.
The CVN-binding studies demonstrated that the compound bound to wild-type and resistant viruses ( Figure 5 ). This implies that binding to some glycosylation sites may not affect virus infectivity. It is evident from the drug sensitivity studies that mutations at positions 63 and 94a cause the virus to become resistant to CVN. Thus, binding of CVN to glycoproteins at these locations causes neutralization of virus infectivity.
Recently Balzarini et al., (2006) prepared CVN resistant forms of HIV and analysed them for mutations. Of eight mutations found, six resulted in the deletion of highmannose type N-glycans on the gp120 molecule. They found that the extent of phenotypic resistance to CVN of the mutated virus strains was related to the number of glycan deletions in the gp120. Hu and colleagues (2007) reported similar types of mutations in HIV isolates that were resistant to CVN. The present studies are the first to report mutations in an influenza virus that confer resistance to CVN, and are consist with the types of mutations found in HIV.
Mutations in the viral HA1 are not the only ones necessary to develop a virus lethal to mice. Other mutations in viral genes not analysed in these studies, such as the virus replication enzymes, are also required for lethality (Brown & Bailly, 1999; Govorkova et al., 2000; Brown et al., 2001 , McCullers et al., 2005 . We felt that it was beyond the scope of this research to investigate these possibilities because mutations other than in the HA gene would not be related to resistance to CVN. We also did not introduce the HA mutations into a standard genetic background by reverse genetics to determine if they were the sole determinants of phenotypic changes associated with mortality. Nevertheless, mutations in the viral HA1 are important to mouse adaptation, particularly those identified in this study, as has been indicated by other investigators (Hartley et al., 1997; Govorkova et al., 2000; Tumpey et al., 2007) .
The studies presented here demonstrate how CVN can be used as a tool to probe for changes in viral glycoprotein structure during mouse adaptation.
